WO2007054309A3 - Utilisation d'acide clodronique pour traiter la podotrochlose - Google Patents

Utilisation d'acide clodronique pour traiter la podotrochlose Download PDF

Info

Publication number
WO2007054309A3
WO2007054309A3 PCT/EP2006/010753 EP2006010753W WO2007054309A3 WO 2007054309 A3 WO2007054309 A3 WO 2007054309A3 EP 2006010753 W EP2006010753 W EP 2006010753W WO 2007054309 A3 WO2007054309 A3 WO 2007054309A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
clodronic acid
navicular syndrome
navicular
syndrome
Prior art date
Application number
PCT/EP2006/010753
Other languages
German (de)
English (en)
Other versions
WO2007054309A2 (fr
Inventor
Michael Frevel
Original Assignee
Omnimedic Gbr
Michael Frevel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007054309(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/084,587 priority Critical patent/US7781420B2/en
Priority to DK06818441.5T priority patent/DK1948194T3/da
Priority to PL06818441T priority patent/PL1948194T3/pl
Priority to ES06818441.5T priority patent/ES2503342T3/es
Priority to AU2006311227A priority patent/AU2006311227B2/en
Application filed by Omnimedic Gbr, Michael Frevel filed Critical Omnimedic Gbr
Priority to EP06818441.5A priority patent/EP1948194B8/fr
Priority to NZ568215A priority patent/NZ568215A/en
Priority to JP2008539340A priority patent/JP5483879B2/ja
Priority to CA2627942A priority patent/CA2627942C/fr
Publication of WO2007054309A2 publication Critical patent/WO2007054309A2/fr
Publication of WO2007054309A3 publication Critical patent/WO2007054309A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'acide clodronique, de ses sels d'addition ou esters, en tant que principe actif préparer un produit pharmaceutique destiné à traiter la podotrochlose à laquelle participe l'ostéoporose chez le cheval.
PCT/EP2006/010753 2005-11-09 2006-11-09 Utilisation d'acide clodronique pour traiter la podotrochlose WO2007054309A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2627942A CA2627942C (fr) 2005-11-09 2006-11-09 Utilisation d'acide clodronique pour traiter la podotrochlose
DK06818441.5T DK1948194T3 (da) 2005-11-09 2006-11-09 Anvendelse af clodronsyre til behandling af hovsenebenssyndrom
PL06818441T PL1948194T3 (pl) 2005-11-09 2006-11-09 Zastosowanie kwasu klodronowego do leczenia zespołu trzeszczkowego
ES06818441.5T ES2503342T3 (es) 2005-11-09 2006-11-09 Uso de ácido clodrónico para el tratamiento de la podotrocleosis
AU2006311227A AU2006311227B2 (en) 2005-11-09 2006-11-09 Use of clodronic acid for the treatment of navicular syndrome
US12/084,587 US7781420B2 (en) 2005-11-09 2006-11-09 Use of clodronic acid for treatment podotrochlosis
EP06818441.5A EP1948194B8 (fr) 2005-11-09 2006-11-09 Utilisation d'acide clodronique pour traiter la podotrochlose
NZ568215A NZ568215A (en) 2005-11-09 2006-11-09 Use of clodronic acid for the treatment of naviculars syndrome
JP2008539340A JP5483879B2 (ja) 2005-11-09 2006-11-09 舟状骨症候群の治療へのクロドロン酸の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005053512.7 2005-11-09
DE102005053512A DE102005053512A1 (de) 2005-11-09 2005-11-09 Verwendung von Clodronsäure zur Behandlung von Podotrochlose

Publications (2)

Publication Number Publication Date
WO2007054309A2 WO2007054309A2 (fr) 2007-05-18
WO2007054309A3 true WO2007054309A3 (fr) 2008-02-07

Family

ID=37946748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/010753 WO2007054309A2 (fr) 2005-11-09 2006-11-09 Utilisation d'acide clodronique pour traiter la podotrochlose

Country Status (12)

Country Link
US (1) US7781420B2 (fr)
EP (1) EP1948194B8 (fr)
JP (1) JP5483879B2 (fr)
AU (1) AU2006311227B2 (fr)
CA (1) CA2627942C (fr)
DE (1) DE102005053512A1 (fr)
DK (1) DK1948194T3 (fr)
ES (1) ES2503342T3 (fr)
NZ (1) NZ568215A (fr)
PL (1) PL1948194T3 (fr)
PT (1) PT1948194E (fr)
WO (1) WO2007054309A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012619A1 (fr) * 1995-09-29 1997-04-10 Novartis Ag Methode de traitement de la maladie naviculaire chez les chevaux
US20010006960A1 (en) * 1998-10-02 2001-07-05 Philippe Du Mesnil Process for treating lameness by administration of a bisphosphonic acid derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US7277744B2 (en) * 1999-03-22 2007-10-02 Schaefer Allan L Early detection of inflammation and infection using infrared thermography
US6280741B1 (en) * 1999-08-19 2001-08-28 Ed C. Jessup Equine treatment and method of administering such treatment
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US6635236B2 (en) * 2001-08-10 2003-10-21 Baer Knut Method for treating podotrochlosis
NZ535178A (en) * 2002-03-11 2007-05-31 Allan L Schaefer Method for the evaluation of velvet antler

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012619A1 (fr) * 1995-09-29 1997-04-10 Novartis Ag Methode de traitement de la maladie naviculaire chez les chevaux
US20010006960A1 (en) * 1998-10-02 2001-07-05 Philippe Du Mesnil Process for treating lameness by administration of a bisphosphonic acid derivative

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENOIX J -M ET AL: "Tiludronate as a new therapeutic agent in the treatment of navicular disease: A double-blind placebo-controlled clinical trial.", EQUINE VETERINARY JOURNAL, vol. 35, no. 4, June 2003 (2003-06-01), pages 407 - 413, XP009092632, ISSN: 0425-1644 *
GRAY A W ET AL: "Generation and activity of equine osteoclasts in vitro: Effects of the bisphosphonate pamidronate (APD)", RESEARCH IN VETERINARY SCIENCE, vol. 72, no. 2, April 2002 (2002-04-01), pages 105 - 113, XP002460164, ISSN: 0034-5288 *
MCGUIGAN M P ET AL: "A double-blind placebo-controlled trial of biphosphonate in the treatment ofnavicular syndrome", PROCEEDINGS OF THE BRITISH EQUINE VETERINARY ASSOCIATION CONGRESS, X, XX, vol. 39, 2000, pages 207, XP001536375 *

Also Published As

Publication number Publication date
DK1948194T3 (da) 2014-10-06
ES2503342T3 (es) 2014-10-06
PL1948194T3 (pl) 2014-12-31
WO2007054309A2 (fr) 2007-05-18
NZ568215A (en) 2011-06-30
JP5483879B2 (ja) 2014-05-07
US20090253657A1 (en) 2009-10-08
CA2627942A1 (fr) 2007-05-18
PT1948194E (pt) 2014-09-24
US7781420B2 (en) 2010-08-24
EP1948194B1 (fr) 2014-07-02
AU2006311227B2 (en) 2012-08-30
JP2009514922A (ja) 2009-04-09
EP1948194A2 (fr) 2008-07-30
EP1948194B8 (fr) 2014-08-13
CA2627942C (fr) 2015-12-29
AU2006311227A1 (en) 2007-05-18
DE102005053512A1 (de) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2006058648A3 (fr) Acides biaryloxymethylarenecarboxyliques
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
WO2010069502A3 (fr) Amides d'acide anthranilique substitués par tétrazol, utilisés comme pesticides
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2011041694A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
WO2008005651A3 (fr) Dérivés d'acide rhodanine-carboxylique cycliques destinés au traitement et à la prévention de la tuberculose
WO2008079610A3 (fr) Nouveaux inhibiteurs d'acétyl-coa-carboxylase (acc) et utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique
WO2007090661A3 (fr) Combinaison de substances actives
WO2011089234A3 (fr) Procédé et composition
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
WO2008073332A3 (fr) Compositions de créatine pour traitement cutané
WO2007079312A3 (fr) Compositions et procédés de traitement d’affections pathologiques médiées par l'actine
WO2008092219A3 (fr) Composition pharmaceutique comprenant du tramadol et du cétoprofène en association
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
WO2007095609A3 (fr) Utilisation de dérivés de benzo-hétéroaryl sulfamide pour le traitement d'une manie et de trouble bipolaire
WO2006099942A3 (fr) Utilisation de 8-n-benzimidazoles a substitution amino
WO2009052942A3 (fr) Stabilisation d'agents thérapeutiques protéiques
WO2007054309A3 (fr) Utilisation d'acide clodronique pour traiter la podotrochlose
WO2007012870A3 (fr) Utilisation therapeutique de nefopam

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2627942

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 568215

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2008539340

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12084587

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006818441

Country of ref document: EP

Ref document number: 2006311227

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006311227

Country of ref document: AU

Date of ref document: 20061109

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006311227

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006818441

Country of ref document: EP